Study of pembrolizumab plus other drugs before lung cancer surgery
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial is testing a new combination of drugs (including pembrolizumab) as a treatment before surgery for people with a certain type of lung cancer. The goal is to see if it helps shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have non-small cell lung cancer that can be removed with surgery (stage II, IIIA, or IIIB N2).
- You must not have had prior treatment for this lung cancer.
- You must be healthy enough for surgery (ECOG score 0 or 1 means you are fully active or able to do light work).
- You must not have certain other eye, nerve, or gut conditions, or be on strong immune-suppressing medications.
- You must not have had another cancer that required treatment in the last 5 years.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug (sacituzumab tirumotecan) to pembrolizumab for people with non-small cell lung cancer that did not completely disappear after initial treatment and surgery. The goal is to see if the combination works better than pembrolizumab alone.
This Phase II trial tests whether a penpulimab-based combination treatment, given before and after surgery, can improve outcomes for people with operable, locally advanced non-small cell lung cancer. It mainly aims to treat the cancer earlier (before surgery) and help prevent it from coming back (after surgery).
This trial tests two different drug combinations (IBI363 plus chemo versus pembrolizumab plus chemo) given before surgery for people with a specific type of lung cancer. The goal is to see which approach works better at shrinking the tumor and helping patients recover.
This trial studies whether adding immune treatment and chemotherapy around the time of lung tumor removal improves outcomes for people with operable non-small cell lung cancer (NSCLC). You may qualify if your cancer can be surgically removed and your tumor tests meet required biomarker rules.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a new drug (adebrelimab) combined with standard chemotherapy, with or without another drug (bevacizumab), given before surgery for people with a certain type of lung cancer. The goal is to see if this combination helps shrink the tumor and makes surgery more effective.
Hear when a new Lung Neoplasm Malignant trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.